MARKET

FIXX

FIXX

Homology Medicines
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.26
+0.49
+3.84%
Opening 13:03 01/22 EST
OPEN
12.71
PREV CLOSE
12.77
HIGH
13.28
LOW
12.65
VOLUME
147.33K
TURNOVER
--
52 WEEK HIGH
22.38
52 WEEK LOW
8.70
MARKET CAP
600.20M
P/E (TTM)
-4.8426
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology NEW YORK--(BUSINESS
Benzinga · 01/12 11:50
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
--New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology
BusinessWire · 01/12 08:45
AY, ABUS, ACLS and FIXX among after-hours movers
Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%.
Seekingalpha · 01/08 22:43
Homology Medicines unveils plans to start three gene therapy programs this year
Homology Medicines ([[FIXX]] +4.3%) has outlined plans to initiate two additional Phase 1/2 dose-escalation trials in 2021 with its gene therapy candidate for Hunter syndrome and gene editing candidate, which is
Seekingalpha · 01/06 16:22
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients -
GlobeNewswire · 01/06 13:00
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
\- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients - \- Company Plans to Nominate Additional Development Candidate in New Therapeutic Area - \- Management Highlights Anticipa...
GlobeNewswire · 01/06 13:00
Alexion, Calyxt, Arvinas: 5 Top Stock Gainers for Monday
Alexion Pharmaceuticals, Calyxt, Homology Medicines, Arvinas and SandRidge Energy are five top stock gainers for Monday.
TheStreet.com · 12/14/2020 18:36
ALXN, SOL, SPCE and AMC among midday movers
Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA) +23%.Losers: Aerpio Pharmaceuticals (ARPO) -48%.Greenwich
Seekingalpha · 12/14/2020 17:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FIXX. Analyze the recent business situations of Homology Medicines through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FIXX stock price target is 28.44 with a high estimate of 37.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 158
Institutional Holdings: 35.08M
% Owned: 77.50%
Shares Outstanding: 45.26M
TypeInstitutionsShares
Increased
26
1.84M
New
43
-698.87K
Decreased
38
3.98M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.59%
Pharmaceuticals & Medical Research
+0.70%
Key Executives
President/Chief Executive Officer/Director/Primary Contact
Arthur Tzianabos
Chief Financial Officer/Treasurer/Secretary
W. Bradford Smith
Chief Scientific Officer
Albert Seymour
Chief Operating Officer
Sam Rasty
Other
Gabriel Cohn
Other
Tim Kelly
Director
Jeffrey Poulton
Independent Director
Steven Gillis
Independent Director
Richard Gregory
Independent Director
Kush Parmar
Independent Director
Matthew Patterson
Independent Director
Alise Reicin
Independent Director
Mary Thistle
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FIXX
Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.
More

Webull offers kinds of Homology Medicines Inc stock information, including NASDAQ:FIXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FIXX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FIXX stock methods without spending real money on the virtual paper trading platform.